Breaking News

Pfizer to Acquire Array BioPharma for $11.4B

Expands innovative biopharma business with multiple targeted investigational cancer therapies and adds a large portfolio of royalty-generating medicines

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer and Array BioPharma Inc. have entered into a definitive merger agreement under which Pfizer will acquire Array, a commercial stage biopharma company focused on targeted small molecules to treat cancer and other diseases, in a transaction valued at approximately $11.4 billion.   Array’s portfolio includes the approved combined use of BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) for the treatment of BRAF mutant unresectable or metastatic melanoma. The combination therapy has sig...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters